BUND FINANCE

BUND FINANCE › Stocks › NTRA

Natera, Inc. (NTRA)

NASDAQ · Stock price, chart and technical analysis

US$289.92+0.4200 (+0.15%)

Data from Financial Modeling Prep · Nov 19, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$289.50
OpenUS$294.75
Day rangeUS$288.16 – US$307.19
52-week rangeUS$181.00 – US$437.41
Market capUS$42.04B
Volume2.73M
50-day averageUS$377.35
200-day averageUS$272.24
Beta1.52

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$625.5MUS$820.2MUS$1.1BUS$1.7BUS$2.3B
Net income−US$471.7M−US$547.8M−US$434.8M−US$190.4M−US$208.2M
EPS (diluted)-5.21-5.57-3.78-1.53-1.52
Gross margin49.1%44.4%45.5%60.3%64.9%
Operating margin-74.9%-66.0%-41.2%-13.1%-13.4%
Net margin-75.4%-66.8%-40.2%-11.2%-9.0%
Free cash flow−US$376.3M−US$479.2M−US$286.2MUS$69.2MUS$109.1M
Total debtUS$397.2MUS$446.2MUS$442.0MUS$187.1MUS$214.4M
CashUS$84.4MUS$466.1MUS$642.1MUS$945.6MUS$1.1B

Compound annual growth: revenue 38.6% · net income — (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E——26.4x
EV / EBITDA——16.3x
Operating margin-9.0%—3.6%
Net margin-5.7%—-0.0%
Debt / equity0.47—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Natera, Inc.

SectorHealthcare
IndustryMedical - Diagnostics & Research
CountryUS
CEOSolomon Moshkevich
Employees6,138
IPO date2015-07-01

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited gen…

www.natera.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice